by sodium dodecyl sulfate polyacrylamide gel electrophoresis (sDs-Page). the enzyme was then dephosphorylated, repurified, and used for the high-throughput screen. aLK1, aLK2, aLK3, aLK4, and other kinases, including protein kinase D (PKD) isozymes, protein kinase c (PKc) isozymes, iκb kinase (iKK) isozymes, P38α, calmodulin-dependent protein kinase (camK) isozymes, protein kinase c-related kinase (PrK) isozymes, cyclin-dependent kinase (cDK) isozymes, glycogen synthase kinase 3β (gsK3β), mitogen-and stress-activated protein kinase 1 (msK1), rho-associated protein kinase (rocK1), checkpoint kinase (chK) isozymes, microtubule affinityregulating kinase (marK) isozymes, and casein kinase 2 (cK2), were purchased from Upstate/millipore (Jersey city, nJ) or invitrogen (carlsbad, ca). Discoidin domain receptor kinase 1 (DDr1) was obtained from carna biosciences (natick, ma). histone deacetylase (hDac) isozymes were expressed and isolated in-house. Lilly compound [3-(Pyridin-2-yl)-4-(4-quinonyl)]-1h-pyrazole, gsK compound 1, 5-naphthyridine aminothiazole, and staurosporine were from calbiochem (emD biochemicals, gibbstown, nJ). adenosine diphosphate (aDP) antibody and aDP tracer were from Upstate/millipore. 11, 15 chymotrypsin, maleate dehydrogenase (mDh), β-lactamase, atP, aDP, and dithiothreitol (Dtt) were obtained from sigma chemical (st. Louis, mo). biotinylated n-terminal smaD2 ser 465 peptide (hLngPLQwLDKVLtQmgsPsVrcssms) was purchased from american Peptide company (sunnyvale, ca). Phospho-smaD antibody was from cell signaling (Danvers, ma). rabbit anti-smaD2/3 primary antibody was from bD transduction Laboratories (franklin Lakes, nJ). ProxiPlate-384 Plus plates were from Perkinelmer (waltham, ma). streptavidincoated 96-well plates were obtained from Promega (madison, wi). all other reagents were of the highest grade commercially available.
Kinase assay for high-throughput screen aLK5 activity was measured by detecting aDP formation from atP using the aDP antibody and aDP tracer with 384-well plates. this is a competitive, time-resolved fluorescence resonance energy transfer (tr-fret) immunoassay, based on the transcreener Kinase tr-fret assay (bellbrook Lab, commercialized as adapta Kinase assay by Upstate/millipore, Jersey city, nJ). the assay was designed as a simple two-step endpoint assay (a 5-µL enzyme reaction followed by addition of 2.5 µL stop and Detect solution) using Perkinelmer ProxiPlate-384 Plus plates. Known aLK5 inhibitor [3-(Pyridin-2-yl)-4-(4-quinonyl)]-1h-pyrazole and nonselective kinase inhibitor staurosporine were used as positive controls. 11 compounds (10 µm in Dmso) from the library were spotted into the 384-well plates using a Labcyte echo 550 Liquid handling system (sunnyvale, ca) prior to the addition of dephosphorylated aLK5 and peptide substrate smaD2. reaction solutions were delivered using a nanoquot (bio-tek instruments, winooski, Vt). reaction was initiated by addition of atP solution. the standard reaction mixture contained 10 µm atP, 20 µm smaD2 peptide, 100 ng of dephosphorylated aLK5 in 50 mm hePes (ph 7.5) containing 10 mm mgcl 2 , 0.01% brij-35, and 1 mm egta in a total volume of 5 µL. after 2 h of incubation at room temperature, 2.5 µL of stop and Detect solution (10 mm eDta, 2 nm europium-labeled anti-aDP antibody, and 6 nm aDP tracer fluor 647) was added. the plate was then further incubated for 30 min at room temperature and read on an enVision 2103 multilabeled reader from Perkinelmer. as with other tr-fret systems, the europium donor is excited using a 340-nm excitation filter with a 30-nm bandpass. energy transfer to the alexa fluor 647 tracer is measured using a filter centered at 665 nm with a 10-nm bandpass. this signal is then referenced to the emission from the europium peak, using a 615-nm, 10-nm bandpass filter. the "emission ratio" is calculated as the 665-nm signal divided by the 615-nm signal.
to confirm the quality of the aDP tr-fret assay, the 96-well plate filter assay was also developed for rhaLK5 using a biotinylated and dephosphorylated casein or smaD2 as a phosphoacceptor as essentially described for other kinases. 18 the assay monitored the transfer of 32 P from 32 P-atP to aLK5 peptide substrate smaD2 or casein. the reaction mixtures contained 20 µm of casein or 20 µm smaD2 peptide, 10 µm [γ-32 P] atP (~1 × 10 5 cpm), 10 mm mgcl 2 , 1 mm Dtt, 0.01% brij-35, 50 mm hePes (ph 7.6), and 100 ng aLK5 in the final volume of 50 µL. after incubation at 25 °c for 120 min, 10 µL of the reaction mixture was withdrawn and added to streptavidin-coated 96-well plates. wells were washed successively with 1.2 mL of 2 m nacl and 1.2 mL of nacl containing 1% h 3 Po 4 , 600 µL h 2 o, and 200 µL 95% ethanol. Plates were allowed to dry in a hood at 25 °c for 1 h, and then 25 µL of scintillation fluid (microscint-20) was added to each well. incorporation of [γ-32 P] atP into peptide substrates was measured using a top-count nXt (Packard, meriden, ct).
Calculation
Primary screen data were analyzed using bioassay software (cambridge soft, cambridge, ma) and subsequently processed using microsoft access (microsoft, redmond, wa) and spot fire software (somerville, ma). Percentage of inhibition was calculated as follows: % inhibition = 100 × (ratio sample -ratio 0% inhibition )/ (ratio 100% inhibition -ratio 0% inhibition ).
the 0% inhibition value comes from a control well lacking inhibitor. the 100% inhibition value comes from a control well containing a saturating amount of staurosporine (10 µm).
Immunofluorescence staining
tgf-β-induced nuclear translocation of smaD2 and smaD3 has been previously demonstrated in multiple cell lines. 19 a549 cells were plated in 96-well corning 3904 plates 5 days prior to staining and grown to 80% to 90% confluency in f-12K media (atcc, manassas, Va) containing 1% penicillin/streptomycin/ glutamine mixture (gibco, grand island, nY) and 10% fetal bovine serum (hyclone, Logan, Ut). on the day of staining, cells were transferred to serum-free media for 2 to 4 h. Dilutions of compounds in Dmso were then added, and cells were incubated for 2 h. next, 10 ng/mL human tgf-β (ebioscience, san Diego, ca) was added, and cells were incubated for 1 h further. after the tgf-β incubation, the cells were washed two times for 1 min each with room temperature 1× phosphate-buffered saline (Pbs), followed by fixation for 20 min in 200 µL of 4% paraformaldehyde in 0.1 m PiPes buffer (ph 6.95), 1 mm egta, and 3 mm mgso 4 . the fixation solution was prewarmed to 37 °c. the cells were then washed with room temperature 1× Pbs, followed by permeabilization with 200 µL of 0.2% triton X-100 in Pbs for 2 min. after permeabilization, the cells were washed with room temperature 1× Pbs, followed by blocking with 5% goat serum (invitrogen, carlsbad, ca), 5% glycerol in Pbs overnight at 4 °c. the serum was then removed and 200 µL of a 1:200 dilution of the rabbit anti-smaD2/3 primary antibody (bD transduction Laboratories) in blocking buffer was added and incubated at room temperature for 2 h. cells were then washed three times for 5 min in room temperature 1× Pbs and further incubated with 200 µL of a 1:400 dilution of goat antirabbit alexa fluor 488-labeled secondary antibody (molecular Probes, carlsbad, ca). after incubation for 1 h at room temperature, the cells were washed three times for 5 min in room temperature 1× Pbs, and then 200 µL of 1× Pbs containing a 1:5000 dilution of the hoechst dye 33342 (invitrogen) stock was added to each well. images were captured using an olympus iX71 microscope configured with DaPi and fitc fluorescent excitation filters, as well as equipped with a Photometrics coolsnap hQ digital camera and meta morph v7.1.3.0 software image analysis package (Universal imaging corp., west chester, Pa). to determine the ic 50 value for each compound, we performed the a-549 cell-based assay using the cellomics array scan hcs system (Pittsburgh, Pa).
Computational methods
compounds were prepared for docking using LigPrep to generate 3D conformations (LigPrep version 2.2, schrodinger, LLc, new York, nY). the docking grids (glide version 5.0, schrodinger, LLc) were generated with the default settings using the 1VJY co-crystal structure of 2-(3-(6-methylpyridin-2-yl)-1h-pyrazol-4-yl)-1,5-naphthyridine with human aLK5. 15 flexible ligand docking was carried out using glide with standard Precision (sP) scoring. for each ligand, the top scoring poses were compared to the binding mode of iVJY along with the other published human aLK5 inhibitor co-crystal structures by visual inspection using maestro (maestro version 8.5, schrodinger, LLc). 20, 21 Other methods selectivity assays with other kinases were performed as described above using the appropriate kinase and biotinylated peptide substrates. 18 Kinetic constants were determined using Prism (graphPad software, La Jolla, ca) and erithacus software (grafit version 5.0, erithacus software Ltd., staines, UK). Protein concentrations were determined by the method of bradford using bovine serum albumin as the standard. 22 sDs-Page was performed as described by Laemmli. 23 Purity of compounds was determined by liquid chromatography/mass spectrometry (Lc/ms). for studies of inhibition at the atP binding site, initial velocity analyses were performed with varying concentrations of atP, a single concentration of smaD2 peptide substrate, and several fixed inhibitor concentrations. for studies of inhibition at the smaD2 peptide binding site, kinase assays were performed with varying concentrations of peptide, a single concentration of atP, and several fixed inhibitor concentrations. Data from inhibition experiments were fit to a competitive model (equation (1)), a noncompetitive model (equation (2)), a mixed inhibition model (equation (3)), or an uncompetitive model (equation (4)). 24, 25 the best-fit figures were selected.
(1)
reSuLtS
Development of a 384-well format ADP TR-FRET assay
Due to the low activity of aLK5, we developed the highthroughput screening (hts) assay (aDP tr-fret) by measuring aDP formation from atP using the aDP antibody and aDP tracer. this is a homogeneous, fluorescence-based immunoassay for the detection of aDP. the new assay is best for low-activity kinases such as aLK5 because most of the signal change occurs in the first 10% to 20% conversion of atP to aDP (data not shown). this is in contrast to kinase assays that measure atP depletion, in which 20% conversion of atP to aDP results in only a 20% signal change. to confirm the quality of the aDP tr-fret assay, the 96-well plate filter assay was also developed for rhaLK5 using a biotinylated n-terminal smaD2 ser 465 peptide (hLngPLQwLDKVLtQmgsPsVrcssms) or dephosphorylated casein as phosphoacceptor as essentially described for other kinases. 18 the assay monitored the transfer of 32 P from 32 P-atP into aLK5 peptide substrate smaD2 or casein. as shown in Figure 1 , staurosporine, a nonselective kinase inhibitor, and [3-(Pyridin-2-yl)-4-(4-quinonyl)]-1h-pyrazole, the reported selective aLK5 atP site inhibitor, 11 exhibited ic 50 values of about 0.5 ± 0.1 µm and 0.1 ± 0.03 µm, respectively. these ic 50 values are in agreement with those found for these compounds under the 32 P-atP assay as described above (data not shown).
Results from HTS
as shown in Figure 2 , using the new aDP tr-fret assay, the screening was successfully completed with an average Z′ factor of 0.8 (Fig. 2, inset) . this high Z′ factor of 0.8 showed that the developed aDP tr-fret assay is excellent in terms of consistent signal and background because in practice, it has been generally found that a Z′ ≥ 0.5 is acceptable for hts. 26 from the library of 420 000 compounds, 1521 compounds that inhibited aLK5 activity by >35% were obtained for the primary screen with a hit rate of 0.36% ( Fig. 2A, B) . of these compounds, 555 were confirmed using the primary screen assay to have aLK5 inhibitory activity (confirmation rate 30%). to select compounds with drug-like physicochemical and pharmacological properties, 555 hits were sorted using criteria such as novel structure, potency, no reactive groups that could covalently modify the amino acid side chains of protein, potency, and so on. 27 based on these criteria, 124 compounds were selected for follow-up (0.029% of the total number screened). among these selected compounds, 79 were readily available in-house or from commercial sources. these compounds were purchased and subjected to repeated dose-response testing, which resulted in the formation of a final hit list of nine compounds with ic 50 values of 12 µm or below. the most potent hit, compound 8 (n-(thiophen 2-ylmethyl)-3-(3,4,5 trimethoxyphenyl)imidazo[1,2β]pyridazin 6-amine) (ic 50 of 0.7 ± 0.1 µm; Fig. 3A) , is structurally different from other known aLK inhibitors (Fig. 3B) . this compound was further characterized for its inhibitory activities against smaD phosphorylation using tgf-β-treated a549 cells.
Compound 8 inhibited TGF-β-induced phosphorylation of SMAD protein
tgf-β-induced nuclear translocation of smaD2/3 has been previously demonstrated in multiple cell lines, including a549 cells. 19 this cell line was used to evaluate the inhibitory activity of compound 8 against the nuclear translocation of smaDs. Figure 4 shows a comparison of untreated cells (Fig. 4A) and tgf-β-treated cells (Fig. 4B) . the immunofluorescent staining is much more concentrated and intense in the nuclei of the treated cells, showing that nuclear translocation of smaD2/3 has occurred in response to tgf-β stimulation. Figure 4c shows an image of cells that were treated with 3 µm of the positive control 1, 5-naphthyridine aminothiazole. 15 the nuclear translocation of smaD2/3 has been inhibited. Figure 4d shows cells treated with compound 8 that exhibited a similar effect with the positive control ( Fig. 4c) . Dmso treatments at the corresponding concentrations did not inhibit the nuclear translocation. to determine the ec 50 value for compound 8, we performed the a549 cell-based assay using the cellomics array scan hcs system. as shown in Figure 5A 8 was confirmed to inhibit tgf-β-induced nuclear translocation of smaD2/3 in a549 cells with an ec 50 value of 0.8 ± 0.3 µm, which is close to that of the ic 50 value found in the in vitro kinase assay (0.7 ± 0.1 µm; Fig. 3A) . the reason for the good potency of compound 8 in the a549 cell-based assay is not clear. to confirm the decreased phosphorylation of smaD protein in the a549 cell-based assay, compound 8 was tested with different concentrations (0, 0.1, 1, and 10 µm). the treated cells were then harvested and extracted with buffer, and smaD phosphorylation was examined using western blot. as shown in Figure 5B , increasing concentration of compound 8 resulted in the decreasing in smaD phosphorylation. the results with compound 8 confirmed the cellomics results (Fig. 4d) namely, that this compound inhibited the tgf-β-induced phosphorylation of smaD protein.
Selectivity of compound 8
next the selectivity of compound 8 was tested with a panel of enzymes that included various kinases and enzymes with different mechanisms (PKD1, iKK1, iKK2, P38α, camK i, camK iV, camK iiδ, PrK1, PrK2, cDK1, cDK2, cDK4, cDK9, gsK3β, msK1, rocK1, chK1, chK2, marK1, marK2, marK3, cK2, asK1, DDr1, hDac1, hDac2, hDac3, chymotrypsin, mDh, β-lactamase). no inhibitory activity of compound 8 was found for other kinases or enzymes as described above at a concentration below 10 µm. it should be noted that although compound 8 exhibited selectivity against our in-house panel of kinases and enzymes, its inhibitory activity must be further tested using the wider panel of kinases and receptors. because tgf-β-activated type i receptors, aLK4 and aLK5, phosphorylate smaD2/3, whereas bmP-activated aLK1, aLK2, and aLK3 phosphorylate smaDs 1, 5, and 8, 1-4 selectivity of compound 8 was also examined against other commercially available aLKs (aLK1, aLK2, aLK3, and aLK4). as shown in Figure 5c , although compound 8 exhibited weak inhibitory activity (~20%) against aLK1, aLK2, and aLK3 at a concentration below 10 µm, it strongly inhibited aLK4 activity with an ic 50 value of 1.4 ± 0.4 µm. selectivity of aLK5 against other aLK isozymes such as aLK1, aLK2, aLK3, and aLK4 will be an important issue for a structure-function relationship study of compound 8.
Kinetic study of compound 8
to define the mechanism of inhibition for compound 8, the effect of atP and smaD2 peptide concentrations in the in vitro aLK5 assay was examined. for studies of inhibition at the atP binding site, initial velocity analyses were performed with varying concentrations of atP, a single concentration 15 immunofluorescence staining was performed as described in materials and methods. of smaD2 peptide substrate, and several fixed inhibitor concentrations. for studies of inhibition at the smaD2 peptide binding site, kinase assays were performed with varying concentrations of peptide, a single concentration of atP, and several fixed inhibitor concentrations. as shown in Figure  5d , double-reciprocal plots of 1/rate versus 1/atP intersected to the left of the y-axis and above the x-axis, indicating that compound 8 inhibited aLK5 activity in a manner that is mixed-type inhibition. the K i and K i ′ were calculated at about 0.2 ± 0.1 µm and 0.5 ± 0.2 µm, respectively. also as shown in Figure 5e , increasing concentrations of smaD2 peptide substrate at a constant concentration of atP did not alter aLK5 activity, indicating that compound 8 is noncompetitive with smaD peptide with a K i value of 0.1 ± 0.01 µm.
Docking study of compound 8
finally, although compound 8 exhibited mixed-type inhibition, we attempted to compare its binding to those of the published atP site aLK5 inhibitors using docking experiments. there are several published aLK5 crystal structures with inhibitors bound. [14] [15] [16] [17] all have a common binding motif in the atP site. each has an inhibitor with a moiety that binds to the backbone of the hinge region (his 283 ), the side chain of Lys 232 , and a water molecule, which is also bound to glu 245 , asp 351 (1)), a noncompetitive model (equation (2)), a mixed inhibition model (equation (3)), or an uncompetitive model (equation (4)). 24, 25 the best-fit figures were selected as described in materials and methods. in the kinase. there seems to be some flexibility with the side chain position of asp 351 , and not all of the inhibitors interact with the aspartic acid. shown in Figure 6A is a schematic drawing of the interactions made with 2-(3-(6-methylpyridin-2-yl)-1h-pyrazol-4-yl)-1,5-naphthyridine from the X-ray structure. 15 the backbone nh of his 283 is involved in the binding of the atP adenine group, and the lysine is involved in the coordination of the atP triphosphate group. this lysine position is conserved across the kinase family. the proposed possible binding mode of compound 8 in the atP site is shown in Figure 6B . the oxygen of the 3-methoxy group can interact with Lys 232 , whereas the adjacent 4-methoxy oxygen can interact with the water. the imidazo nitrogen makes a hydrogen bond with the nh of the his 283 backbone in the hinge. [14] [15] [16] [17] this puts the thiophene group heading out toward the solvent. this compound does not interact with asp 351 . in Figure 6c is an overlay of compound 8 compared to 2-(3-(6-methylpyridin-2-yl)-1h-pyrazol-4-yl)-1,5-naph-thyridine from the 1VJY crystal structure. [14] [15] [16] [17] the above results suggest that compound 8 still can potentially make some of the known key interactions with the aLK5 but not in a similar binding mode of those of the published atP site inhibitors. [14] [15] [16] [17] results from an X-ray crystallographic study of an aLK5compound 8 complex will provide more detailed information regarding the binding site of compound 8. dIScuSSIon a number of atP site aLK5 inhibitors have been found to effectively attenuate progressive fibrosis in kidney, liver, and lung and kidney fibrosis associated with diabetes in the db/db mouse, [9] [10] [11] [12] [13] although their pharmacological effect and clinical efficacy in the treatment of fibrosis have not been reported. in the present study, to discover a unique inhibitor for aLK5, we developed a 384-well format aDP tr-fret assay by detecting aDP formation from atP using dephosphorylated aLK5 (Fig. 1) . from the hts campaign ( Fig. 2) and follow-up characterization of the final hits, we identified a structurally novel compound (compound 8) (n-(thiophen 2-ylmethyl)-3-(3,4,5 trimethoxyphenyl) imidazo[1,2β]pyridazin 6-amine) that strongly inhibited aLK5 both in vitro and smaD phosphorylation using tgf-β-treated a549 cell-based assays (Figs. 3-5) . the kinetic study indicated that compound 8 inhibited aLK5 activity in a manner that is mixed-type inhibition against atP (Fig. 5) . together with results from docking experiments (Fig. 6) , the above results suggest that compound 8 may not interact with aLK5 in a similar binding mode of those of the published atP site inhibitors. 9-17 compound 8 may be useful in the design of the next generation of the aLK5 inhibitor for fibrotic diseases.
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